Idogen AB
Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs, and the body's own cells or tissues in Sweden. The company's advanced product candidate is IDO 8 that is designed for patients with severe haemophilia A, who have developed neutralizing antibodies against critical treatment wi… Read more
Idogen AB (IDOGEN) - Total Liabilities
Latest total liabilities as of March 2023: Skr3.09 Million SEK
Based on the latest financial reports, Idogen AB (IDOGEN) has total liabilities worth Skr3.09 Million SEK as of March 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Idogen AB - Total Liabilities Trend (2014–2022)
This chart illustrates how Idogen AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Idogen AB Competitors by Total Liabilities
The table below lists competitors of Idogen AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Advanced Health Intelligence Ltd.
OTCGREY:MYZQF
|
USA | $10.26 Million |
|
Seya Industries Limited
NSE:SEYAIND
|
India | ₹7.87 Billion |
|
BAVARIA INDUSTR
MU:B8A
|
Germany | €51.29 Million |
|
Argent
JSE:ART
|
South Africa | ZAC899.39 Million |
|
International Prospect Ventures Ltd
PINK:URANF
|
USA | $239.03K |
|
CKALF
PINK:CKALF
|
USA | $53.44 Million |
|
PRYSMIAN - Dusseldorf Stock Exchang
DU:AEU
|
Germany | €9.42 Billion |
Liability Composition Analysis (2014–2022)
This chart breaks down Idogen AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.52 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Idogen AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Idogen AB (2014–2022)
The table below shows the annual total liabilities of Idogen AB from 2014 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | Skr5.38 Million | -55.44% |
| 2021-12-31 | Skr12.08 Million | +18.20% |
| 2020-12-31 | Skr10.22 Million | -20.51% |
| 2019-12-31 | Skr12.86 Million | -37.73% |
| 2018-12-31 | Skr20.65 Million | +380.39% |
| 2017-12-31 | Skr4.30 Million | +107.49% |
| 2016-12-31 | Skr2.07 Million | +86.48% |
| 2015-12-31 | Skr1.11 Million | +115.13% |
| 2014-12-31 | Skr516.43K | -- |